'Probably going to be the most prescribed drug'; The future of weight loss drugs
Drugs like Ozempic, Wegovy and Mounjaro are changing the game for weight loss.  GLP-1 medications were originally intended to treat type 2 diabetes, but a growing number of people are using it for weight loss.
GLP-1 Drugs For Weight Loss Aren’t Cost-Saving Yet
Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug spending. But thus far, the data don’t show this.
Hanmi seeks to gain on Wegovy with its own weight-loss drug
Hanmi Pharmaceutical Senior Vice President Choi In-young, head of the R&D center, speaks to Korean media outlets at a press conference held in San Francisco, California, on Jan. 15. [LEE JAE-LIM] SAN FRANCISCO — Hanmi Pharmaceutical aims to disrupt the obesity drug market currently led by Eli Lilly and Novo Nordisk with its own diverse range of weight-loss treatments tailored to meet the unique needs of patients,
Eli Lilly was hoping for even greater weight loss drug demand
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
New weight loss pill to be approved by early 2026: Eli Lilly
The weight loss pill aims to compete with popular injectable treatments like Eli Lilly's own Zepbound and Novo Nordisk's Wegovy, which currently dominate the space. If approved, orforglipron would offer a pill alternative to the current injectables,
Hosted on MSN28m
US Doctor Claims Weight Loss Drug, GLP-1, Leads To Suicidal Thoughts And Behaviors
A study found that disruptions in homeostasis from quick weight reduction by consuming GLP-1 drug can elevate cortisol - a ...
Healio12h
Top in endocrinology: Novel GLP-1 lowers weight; osteoporosis detection with CT plus AI
Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...
Employee Benefit News12h
A guide to GLP-1 adoption: How employers can add this benefit in 2025
While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...
GLP-1 weight loss medications pose challenges for c-stores. Here’s how retailers can respond.
Users of Ozempic and other drugs are shunning items like energy drinks and salty snacks, research shows. But there are ...
24/7 Wall St. on MSN15h
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
Civic Science on MSN8h
GLP-1 Trends by CivicScience: Current Users Report Shifts in Retail Shopping and Alcohol Consumption, Plus More Insights
This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.
Maker of weight-loss drugs to ask Trump to pause price negotiations: Report
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...
5 Best Weight Loss Solutions of 2025: Your Guide to Achieving Lasting Results
Each brand has its own formula for helping users achieve their weight loss goals. Their methods include remote healthcare ...
As Lilly Stock Tumble on GLP-1 Demand Worries, CEO Says All Is Well
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.